share_log

Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights

Benzinga ·  11/07 21:00

5 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings23000
Last 30D00000
1M Ago11000
2M Ago01000
3M Ago11000

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.4, a high estimate of $20.00, and a low estimate of $15.00. This current average has increased by 0.87% from the previous average price target of $17.25.

bigjpg

Breaking Down Analyst Ratings: A Detailed Examination

The perception of Amicus Therapeutics...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    コメントする